Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Reneuron Group Plc LSE:RENE London Ordinary Share GB00BF5G6K95 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  8.00 7.37% 116.50 115.00 118.00 116.50 107.50 108.50 287,149 12:56:44
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 6.1 -13.9 -35.9 - 66

Reneuron Share Discussion Threads

Showing 8276 to 8299 of 8325 messages
Chat Pages: 333  332  331  330  329  328  327  326  325  324  323  322  Older
DateSubjectAuthorDiscuss
07/6/2021
17:45
Ref: IPSC's With thanks to PhilBanks on t'other site: Cell & Gene Meeting on the Med – CEO Investor Presentation. . . . https://www.youtube.com/watch?v=wKco5BP1IFo&ab_channel=ReNeuronLimited H.C. Wainwright Global Life Sciences Conference. . . . https://www.youtube.com/watch?v=sbf_MpyiZWE&ab_channel=ReNeuronLimited Both are presented by Olav, and the content is pretty similar. They also both finish with interesting comments regarding the iPSC platform, if you want to skip to the final 30s or so. 1st video: ". . . and there's another programme that I haven't talked about, which is the iPSCs where we also have huge potential over the next few months. . . " 2nd video: ". . . I didn't go into the iPSCs any further, please go to our website to look at that. It is an earlier stage programme than the exosomes, but the potential is enormous . . ."
bradders51
07/6/2021
13:54
I seem to remember there are several data points coming up in the next month or so? I also found the below on the website. not sure I had seen any references to this side of the gene therapy platforms before. looks and sounds exciting hxxp://www.reneuron.com/products/induced-pluripotent-stem-cell-ipsc-platform/
bg23
04/6/2021
10:08
Bounce overdue, perhaps; but it needs to rise over 1.50 before we can get remotely excited. Beyond that, the gap up looks towards £2 and £2.50. Strong hold afaic.
brucie5
04/6/2021
09:50
Chart looking good. Let's hope the fundamentals give a reason for optimism.
dickbush
28/5/2021
13:56
Interesting trade of 255k @ 126p paid gone through. A penny premium for a nice sum.
tole
24/5/2021
22:04
http://news.sky.com/story/gene-therapy-breakthrough-helps-blind-man-regain-some-vision-after-40-years-12316058
jpuff
20/5/2021
11:38
Has Dr Corteling left Rene, as I thought he was Chief Scientific Officer?
stutes
16/5/2021
15:46
Biogen reveals gene therapy trial failure as investors remain laser-focused on aducanumab drama hTtps://www.fiercebiotech.com/biotech/biogen-reveals-gene-therapy-trial-failure-as-investors-remain-laser-focused-aducanumab A gene therapy approach to RP has failed. That therapy came out of a $877 million deal for British biotech Nightstar Therapeutics. We know that Reneuron's RP 12 month results look good, makes the company's market cap of £70m look a bit of a bargain ?
pdt
13/5/2021
15:27
The problem is that Oxford eye hospital is still not recruiting according to clinicaltrials.gov. The big hope was that by adding Oxford's Professor Maclaren Reneuron would boost the trial's profile.
whatno
13/5/2021
12:57
Brad. I have but this has certainly gone down more then others. RP study too early for result but hopefully early positive indications would be nice!!
joeblogg2
13/5/2021
10:26
joe. Have you not seen the majority of other share prices ??
bradders51
13/5/2021
08:58
Bouncing off 150.
masingi
13/5/2021
08:56
What is happening here , continued slide last few days!!
joeblogg2
05/5/2021
14:14
Looks very promising, albeit a speculative situation; and willing to give Michael Taylor and Richard Griffiths between them some benefit of the doubt. Over 1.50 the chart would look very good indeed.
brucie5
05/5/2021
08:21
Lot of small buys this morning
bigspuds
03/5/2021
11:49
Are we due an update on the RP trial? I think the last presentation said they would give news at key annual conferences and one of them is ARVO which is this week ?? Or did they mean the one in 2022? The other two mentioned happen in October and November.
pdt
30/4/2021
15:35
Apparently they might get its use extended to other eye problems? That could be a worry.
rayrac
30/4/2021
08:19
As you can see, zho. I found the news item and corrected. Developed by Spark Therapeutics which was acquired by Hoffmann-La Roche for $4.3 billion in December 2019.
dickbush
30/4/2021
08:07
£600,000 cost, not £60,000 according to https://www.bbc.co.uk/news/health-56906002: "In 2019 the NHS agreed to fund the treatment, Luxturna, the first in a new generation of gene therapies for conditions causing blindness. It costs about £600,000 per patient to treat both eyes, though the NHS has agreed a confidential discount with the makers Novartis."
zho
30/4/2021
08:03
I saw it, too. As we know, it's for the treatment of a very small percentage of the potential market. Didn't they say the NHS was getting a discount from the normal £600,000 cost of treatment? If anything, that suggests enormous revenue potential for RENE's RP treatment if, IF, the trials go well. 2021 looks like a very important year for RENE. https://www.bbc.co.uk/news/health-56906002
dickbush
29/4/2021
19:43
If it’s that bbc article, it’s about luxturna for Lca.
philh75
29/4/2021
19:33
Bit in the news this evening about something similar to rene treatment of the eye. No mention of rene though! Anyone besides me seen it?
rayrac
29/4/2021
12:16
A I said, I'm looking for 300p ++
small crow
29/4/2021
07:33
We have also included the milestones from Fosun for CTX and hRPC. We judge the Company has less control over the timelines for development and we therefore include only the milestones at this stage until more detail is provided. After netting off the corporate expenses and cash, we arrive at a fair value for RENE at 359 pence per share. http://www.allenbycapital.com/research/research-rene_6_3020408471.pdf
zho
Chat Pages: 333  332  331  330  329  328  327  326  325  324  323  322  Older
ADVFN Advertorial
Your Recent History
LSE
RENE
Reneuron
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210613 18:53:52